Highlights Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Delayed Nasdaq Other stock markets 10:48:58 17/05/2024 pm IST			5-day change	1st Jan Change
1.745 ^USD	-0.29%		+2.65%	+4.49%

13/05	Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/04	Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	08/04	CI
Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA	28/03	MT
Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia	28/03	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Milestone Pharma Shares Rise 25% After Plans to Resubmit Etripamil NDA	26/02	DJ
Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt	26/02	CI
Milestone Pharmaceuticals Says FDA Issued Refusal-to-File Letter for New Drug Application for Etripamil; Shares Fall Pre-Bell	26/12	MT
Milestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDA	26/12	DJ
Milestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File Letter	26/12	DJ
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT	26/12	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Milestone Pharmaceuticals Inc. Announces Submission of New Drug Application to the U.S. FDA for Etripamil	24/23/24	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Milestone Pharmaceuticals Inc. Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in the Lancet	20/23/20	CI
Milestone Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
UIL sells holdings in both AssetCo and BNK Banking	29/23/29	AN
Earnings Flash (MIST) MILESTONE PHARMACEUTICALS Posts Q4 Revenue $3.5M	29/23/29	MT
Milestone Pharmaceuticals Inc. Enters into a Purchase and Sale Agreement with RTW Investments, LP and Certain of Its Affiliates	28/23/28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Highlights

Filters